ENXTAM:PHARMBiotechs
Pharming Group (ENXTAM:PHARM) Returns To Profitability Challenging Cautious Earnings Narratives
Pharming Group (ENXTAM:PHARM) has wrapped up FY 2025 with fourth quarter revenue of US$106.5 million and basic EPS of US$0.008, while trailing twelve month figures stand at US$376.1 million in revenue and basic EPS of US$0.004. This frames a year where profitability on a full year basis edges into positive territory. The company has seen quarterly revenue move from US$92.7 million in Q4 2024 and US$74.8 million in Q3 2024 to US$106.5 million in Q4 2025. Over the same period, quarterly basic...